Gotowe bibliografie tematyczne / Migraines

Gotowa bibliografia na temat „Migraines”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 20 lutego 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Migraines”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Migraines"

1

Yamanaka, Gaku, Soken Go, Shinichiro Morichi, Mika Takeshita, Natsumi Morishita, Shinji Suzuki, Takamatsu Tomoko i in. "Clinical Features and Burden Scores in Japanese Pediatric Migraines With Brainstem Aura, Hemiplegic Migraine, and Retinal Migraine". Journal of Child Neurology 35, nr 10 (1.06.2020): 667–73. http://dx.doi.org/10.1177/0883073820927840.

Pełny tekst źródła
Streszczenie:
Background: Migraines are a broad spectrum of disorders classified by the type of aura with some requiring attentive treatment. Vasoconstrictors, including triptans, should be avoided in the acute phase of migraines with brainstem aura, in hemiplegic migraine, and in retinal migraine. This study investigated the characteristics and burden of these migraines. Methods: Medical charts of 278 Japanese pediatric patients with migraines were retrospectively reviewed. Migraine burden of migraines with brainstem aura, hemiplegic migraines, and retinal migraine was assessed using the Headache Impact Test-6™ (HIT-6) and the Pediatric Migraine Disability Assessment scale (PedMIDAS). Results: Of 278 patients screened, 12 (4.3%) patients with migraines with brainstem aura (n = 5), hemiplegic migraines (n = 2), and retinal migraine (n = 5) were enrolled in the study. All patients had migraine with/without typical aura, whereas some patients had coexisting migraine with another type of headache (chronic tension-type headache in 3 patients, and 1 each with frequent episodic tension-type headache, headache owing to medication overuse, and chronic migraine). Migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients with coexisting headaches had higher HIT-6 or PedMIDAS scores, whereas migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients without coexisting headache did not show high HIT-6 or PedMIDAS scores. Conclusion: All migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients experienced migraine with or without typical aura, and some patients having other coexisting headaches also had high PedMIDAS and HIT-6 scores. PedMIDAS and HIT-6 should not be considered diagnostic indicators of migraines with brainstem aura, hemiplegic migraines, or retinal migraine. In clinical practice for headaches in children, careful history taking and proactive assessment of the aura are needed for accurate diagnosis of migraines with brainstem aura, hemiplegic migraines, and retinal migraine.
Style APA, Harvard, Vancouver, ISO itp.
2

Yamanaka, Gaku, Shinji Suzuki, Natsumi Morishita, Mika Takeshita, Kanako Kanou, Tomoko Takamatsu, Shinichiro Morichi i in. "Experimental and Clinical Evidence of the Effectiveness of Riboflavin on Migraines". Nutrients 13, nr 8 (29.07.2021): 2612. http://dx.doi.org/10.3390/nu13082612.

Pełny tekst źródła
Streszczenie:
Riboflavin, a water-soluble member of the B-vitamin family, plays a vital role in producing energy in mitochondria and reducing inflammation and oxidative stress. Migraine pathogenesis includes neuroinflammation, oxidative stress, and mitochondrial dysfunction. Therefore, riboflavin is increasingly being recognized for its preventive effects on migraines. However, there is no concrete evidence supporting its use because the link between riboflavin and migraines and the underlying mechanisms remains obscure. This review explored the current experimental and clinical evidence of conditions involved in migraine pathogenesis and discussed the role of riboflavin in inhibiting these conditions. Experimental research has demonstrated elevated levels of various oxidative stress markers and pro-inflammatory cytokines in migraines, and riboflavin’s role in reducing these marker levels. Furthermore, clinical research in migraineurs showed increased marker levels and observed riboflavin’s effectiveness in reducing migraines. These findings suggest that inflammation and oxidative stress are associated with migraine pathogenesis, and riboflavin may have neuroprotective effects through its clinically useful anti-inflammatory and anti-oxidative stress properties. Riboflavin’s safety and efficacy suggests its usefulness in migraine prophylaxis; however, insufficient evidence necessitates further study.
Style APA, Harvard, Vancouver, ISO itp.
3

Flynn, Niamh. "Psychological Considerations in the Etiology and Pathophysiology of Migraines". OBM Neurobiology 05, nr 02 (18.03.2021): 1. http://dx.doi.org/10.21926/obm.neurobiol.2102092.

Pełny tekst źródła
Streszczenie:
Although studies to understand the pathogenesis of migraines are in progress, no theory has adequately explained the etiology and pathophysiology of migraines to date. This has affected the development of treatment strategies for migraineurs. Currently, the pharmacological treatment for migraines provides both acute and prophylactic options to patients based on a biomedical model of pain. However, patients’ adherence to oral migraine preventive medication (OMPM) is poor, and their persistence is even lower when they cycle through a variety of OMPMs [1]. Although our understanding of the pathophysiology of migraines within the context of the current biopsychosocial model of pain has advanced in recent years, there is a need to better understand the role of social and psychological factors in the pathophysiology of this debilitating disease, which would pave the way for the development and acceptance of more diverse and inclusive treatments. In this review, we provide an overview of the various theories that purport to explain the pathogenesis of the headache phase of migraines, examine the usefulness and shortcomings of these theories, and investigate how psychological considerations may help develop treatments to assist migraine sufferers in managing their headaches better.
Style APA, Harvard, Vancouver, ISO itp.
4

Lee, Sang-Hwa, Jong-Ho Kim, Young-Suk Kwon, Jae-June Lee i Jong-Hee Sohn. "Risk of Vestibulocochlear Disorders in Patients with Migraine or Non-Migraine Headache". Journal of Personalized Medicine 11, nr 12 (8.12.2021): 1331. http://dx.doi.org/10.3390/jpm11121331.

Pełny tekst źródła
Streszczenie:
Headaches, especially migraines, have been associated with various vestibular symptoms and syndromes. Tinnitus and hearing loss have also been reported to be more prevalent among migraineurs. However, whether headaches, including migraine or non-migraine headaches (nMH), are associated with vestibular and cochlear disorders remains unclear. Thus, we sought to investigate possible associations between headache and vestibulocochlear disorders. We analyzed 10 years of data from the Smart Clinical Data Warehouse. In patients with migraines and nMH, meniere’s disease (MD), BPPV, vestibular neuronitis (VN) and cochlear disorders, such as sensorineural hearing loss (SNHL) and tinnitus, were collected and compared to clinical data from controls who had health check-ups without headache. Participants included 15,128 with migraines, 76,773 patients with nMH and controls were identified based on propensity score matching (PSM). After PSM, the odds ratios (OR) in subjects with migraine versus controls were 2.59 for MD, 2.05 for BPPV, 2.98 for VN, 1.74 for SNHL, and 1.97 for tinnitus, respectively (p < 0.001). The OR for MD (1.77), BPPV (1.73), VN (2.05), SNHL (1.40), and tinnitus (1.70) in patients with nMH was also high after matching (p < 0.001). Our findings suggest that migraines and nMH are associated with an increased risk of cochlear disorders in addition to vestibular disorders.
Style APA, Harvard, Vancouver, ISO itp.
5

Adeney, KL, JL Flores, JC Perez, SE Sanchez i MA Williams. "Prevalence and Correlates of Migraine Among Women Attending a Prenatal Care Clinic in Lima, Peru". Cephalalgia 26, nr 9 (wrzesień 2006): 1089–96. http://dx.doi.org/10.1111/j.1468-2982.2006.01171.x.

Pełny tekst źródła
Streszczenie:
Migraine headaches are among the leading causes of disability in the world. The burden of migraines is highest in women of reproductive age. This cross-sectional study characterized the prevalence, symptoms and correlates of migrainous headaches in 154 pregnant women attending a prenatal care clinic in Lima, Peru. Lifetime prevalence of migraine defined by modified IHS criteria was 9.1± (95± CI 4.6–13.6). When probable migraines were included, the lifetime prevalence of migraine in this population was 29.2± (95± CI 22.0–36.4). Migraine headaches were associated with a maternal history of headache, childhood carsickness, a diagnosis of allergies, and a high frequency of fatigue. Although headache-related disability was low in terms of missed work and recreation, high rates of headache pain and medicinal use reflect the true impact on this population.
Style APA, Harvard, Vancouver, ISO itp.
6

Rodríguez-Almagro, Daniel, Alexander Achalandabaso-Ochoa, Esteban Obrero-Gaitán, María C. Osuna-Pérez, Alfonso Javier Ibáñez-Vera i Rafael Lomas-Vega. "Sleep Alterations in Female College Students with Migraines". International Journal of Environmental Research and Public Health 17, nr 15 (29.07.2020): 5456. http://dx.doi.org/10.3390/ijerph17155456.

Pełny tekst źródła
Streszczenie:
Background: Many factors are thought to potentially trigger migraines, among which sleep disturbances are one of the most frequently reported. Both sleep disorders and migraines affect more women than men. This study aims to analyze sleep alterations in young adult women with migraines and how they are related to the presence, frequency, intensity, and disability of migraines in this population. Methods: Fifty-one female university students with physician-diagnosed migraines and 55 healthy female university students completed surveys assessing demographic information and frequency, intensity, and disability of migraines and sleep quality variables. Results: No differences in sleep quality were found between migraine subjects and healthy women (p = 0.815), but women with migraines presented higher daytime somnolence (p = 0.010), greater sleep disruptions (p = 0.002), and decreased sleep adequacy (p = 0.019). The presence of a migraine was significantly related to daytime somnolence (p = 0.003) and sleep disruptions (p = 0.021). Migraine-related disability was associated with sleep disruptions (p = 0.002), snoring (p = 0.016), and a decreased quantity of sleep (p = 0.040). Migraine frequency was related to sleep disturbance (p = 0.003) and snoring (p < 0.001). The intensity of migraines was associated with sleep disruptions (p = 0.004). Conclusions: Our results suggest a relationship between migraines and sleep alterations.
Style APA, Harvard, Vancouver, ISO itp.
7

Suzuki, Keisuke, Yasuyuki Okuma, Tomoyuki Uchiyama, Masayuki Miyamoto, Ryuji Sakakibara, Yasushi Shimo, Nobutaka Hattori i in. "The prevalence, course and clinical correlates of migraine in Parkinson’s disease: A multicentre case-controlled study". Cephalalgia 38, nr 9 (26.10.2017): 1535–44. http://dx.doi.org/10.1177/0333102417739302.

Pełny tekst źródła
Streszczenie:
Background Previous studies have reported a lower migraine prevalence in Parkinson’s disease (PD) patients and improvements in migraine headaches after PD onset, but the clinical association of migraines with PD is unclear. Methods We analysed headache and migraine prevalence and clinical correlates in 436 PD patients (mean age, 69.3 ± 7.8 years) and 401 age- and sex-matched controls (mean age, 69.2 ± 8.6 years) in a case-controlled, multicentre study. Migraines were diagnosed by a questionnaire developed according to the International Classification of Headache Disorders, second edition. We evaluated changes in headache intensity, frequency and severity over several years around the onset of PD among PD patients with headaches or migraines, and over the past several years among control subjects with headaches or migraines. Results PD patients had lower lifetime (9.6% vs. 18.0%) and 1-year (6.7% vs. 11.0%) migraine prevalences than controls. However, lifetime (38.5% vs. 38.9%) and 1-year (26.1% vs. 26.2%) headache prevalence did not differ between PD patients and controls. After adjusting for gender, timing of the evaluation of headache changes, and recall period, PD patients with headaches or migraines exhibited a pronounced reduction in the intensity, frequency and overall severity of their headaches and migraines after the onset of PD compared with controls with headaches or migraines. PD patients with migraines exhibited a higher rate of depression and higher Pittsburgh Sleep Quality Index and PD sleep scale-2 scores than those without headaches. Conclusion While overall headache and migraine severity reduced after PD onset, the presence of migraines was associated with sleep disturbances and depression in PD patients.
Style APA, Harvard, Vancouver, ISO itp.
8

Fu, Xianguo, Jing Yang, Xiaoyang Wu, Qifang Lin, Yuli Zeng, Qiaoqing Xia, Luoyuan Cao, Baoying Huang i Genbin Huang. "Association between PRDM16, MEF2D, TRPM8, LRP1 gene polymorphisms and migraine susceptibility in the She ethnic population in China". Clinical and Investigative Medicine 42, nr 1 (23.03.2019): E21—E30. http://dx.doi.org/10.25011/cim.v42i1.32389.

Pełny tekst źródła
Streszczenie:
Background: The prevalence of migraines in the She population, a minority in China, is significantly higher than that in Han Chinese and other Asian populations. Two single nucleotide polymorphisms (SNPs) have been found to be associated with migraine susceptibility in the She population. Purpose: This study investigated four SNPs, identified in genome-wide association studies, within migraine-susceptible loci in Han Chinese for their association with migraine susceptibility in the She population. Methods: Two-hundred unrelated migraine patients and 200 healthy controls were recruited. The SNPs examined included rs2651899 (PRDM16 ), rs2274316 (MEF2D ), rs7577262 (TRPM8) and rs11172113 (LRP1). Genotyping of the SNPs was performed by allele-specific polymerase chain reaction and direct sequencing. Results: No significant differences between the participants with migraines and controls (participants without migraines) were demonstrated in genotypes, alleles and allele carriage frequencies for the four SNPs. A subgroup analysis found that migraine with aura had a lower frequency of C allele positivity in rs2651899 than in healthy controls (59.6% vs. 74.5%, respectively; P < 0.034). Univariate analyses indicated that no genotype of the four SNPs had a significant association with migraines. Males had a lower risk of migraines, and advanced age was a significant risk factor for migraines in females. Conclusion: The SNPs in four migraine susceptible loci in Han Chinese were not risk factors for migraines in a relatively small sample of the She population.
Style APA, Harvard, Vancouver, ISO itp.
9

Dima, Lorena, Andreea Bălan, Marius Alexandru Moga, Cătălina Georgeta Dinu, Oana Gabriela Dimienescu, Ioana Varga i Andrea Elena Neculau. "Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines". Toxins 11, nr 8 (8.08.2019): 465. http://dx.doi.org/10.3390/toxins11080465.

Pełny tekst źródła
Streszczenie:
Background: In 1989, Botulinum toxin (BoNT) was accepted by the FDA for the management of some ophthalmic disorders. Although it was initially considered a lethal toxin, in recent times, Botulinum toxin A (BoNT-A), which is the more used serotype, has expanded to cover different clinical conditions, primarily characterized by neuropathic pain, including migraines and headaches. Evidence suggests that migraines are influenced by hormonal factors, particularly by estrogen levels, but very few studies have investigated the prevalence and management strategies for migraines according to the hormonal status. The effects of several therapeutic regimens on migraines have been investigated, but the medications used varied widely in proven efficacies and mechanisms of action. BoNT-A is increasingly used in the management of migraine and several placebo-controlled trials of episodic and chronic migraine are currently underway. This paper is a review of the recently published data concerning the administration of BoNT-A in the prevention of chronic migraines. Considering the lack of population-based studies about the effectiveness of BoNT-A in the alleviation of premenstrual and perimenopausal migraines, this study proposes a new perspective of the therapeutic approach of migraine syndrome associated with menopausal transition and the premenstrual period. Methods: We selected the reviewed papers from CrossRef, PubMed, Medline, and GoogleScholar, and a total of 21 studies met our inclusion criteria. Results: To date, no specific preventive measures have been recommended for menopausal women with migraines. BoNT-A often reduces the frequency and intensity of migraine attacks per month; the treatment is well tolerated and does not exhibit a significantly higher rate of treatment-related side effects. No population-based studies were conducted in order to highlight the role of BoNT-A in menopause-related migraines, neither in menstrual migraines. Conclusion: There is a need for further research in order to quantify the real burden of menstrual and perimenopausal migraines and to clarify if BoNT-A could be used in the treatment of refractory postmenopausal and premenstrual migraines.
Style APA, Harvard, Vancouver, ISO itp.
10

Simic, Svetlana, Petar Slankamenac, Milan Cvijanovic, Sofija Banic-Horvat, Zita Jovin i Miroslav Ilin. "Menstrual migraine". Medical review 60, nr 9-10 (2007): 449–52. http://dx.doi.org/10.2298/mpns0710449s.

Pełny tekst źródła
Streszczenie:
Introduction. The prevalence of migraine in childhood and adolescence has not changed to a great extent, but it increases in adolescence, especially in female adolescents. Menstrual migraine ? definition. There are two types of menstrual migraine: true menstrual migraine and menstrual related migraine. True menstrual migraine occurs predominantly around menstruation, whereas menstrual related migraine occurs during menstruation, but also at other times during the month. Causes. Exaggerated or abnormal neurotransmitter responses to normal cyclic changes in the ovarian hormones are probably the basic cause of menstrual migraines. The fall in estrogen levels during menstrual cycle is trigger for the menstrual migraine. Symptoms. Menstrual migraine has the same symptoms as other types of migraine, but the pain is stronger, IT lasts longer, AND IT IS more frequent than other types of migraines. Diagnosis. In order to make a diagnosis, women are asked to keep a headache diary for three months. If the migraine headache is severe and occurs regularly between two days before and three days after the start of menstrual bleeding, it is true menstrual migraine. Therapy. Menstrual migraines are more difficult to treat than other types of migraines. Treatment principles for menstrual migraine are the same as for migraines in general, with certain particularities. Conclusion. Hormonally associated migraine is a specific clinical entity. It is important to diagnose the type of migraine, considering the fact that a decline in estrogen level at the end of menstrual cycle triggers migraine, so it can be treated by low levels of estrogen. .
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Migraines"

1

Tamin, Onésime. "Etude et traitement de l'hémipéricranalgie(migraine) thèse pour le doctorat en médecine présentée et soutenue le 11 juillet 1866 /". Paris : BIUM, 2004. http://www.bium.univ-paris5.fr/histmed/medica/cote?TPAR1860x119.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Molènes, jean Jacques Marc de. "De la migraine thèse pour le doctorat en médecine présentée et soutenue le 25 juillet 1853 /". Paris : BIUM, 2004. http://www.bium.univ-paris5.fr/histmed/medica/cote?TPAR1853x173.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Soula, P. Ch Eugène. "Contribution à l'étude de la migraine". Paris : BIUM, 2004. http://www.bium.univ-paris5.fr/histmed/medica/cote?TPAR1884x035.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Sundholm, James, i n/a. "Analysis of Specific Migraine Candidate Genes Mapping to Human Chromosome 1". Griffith University. School of Health Science, 2003. http://www4.gu.edu.au:8080/adt-root/public/adt-QGU20030829.153348.

Pełny tekst źródła
Streszczenie:
Migraine, comprised of migraine with aura (MA) and migraine without aura (MO), is a painful neurovascular disease, affecting approximately 16% of the general population. It is characterised by a wide variety of symptoms including headache, nausea and vomiting, and photo- and phonophobia. The disorder is complex involving not only multiple genes, but also specific environmental factors, which can induce attacks in genetically predisposed individuals. Hyperhomocysteinaemia is a known risk factor for cerebrovascular, peripheral vascular and coronary heart disease. The Methylenetetrahydrofolate Reductase (MTHFR) enzyme is involved in homocysteine metabolism. Furthermore, it has been reported that a homozygous mutation (677C to T; Ala to Val) in the 5,10-MTHFR gene is associated with an elevation in plasma homocysteine levels (Frosst et al., 1995). This common mutation in the MTHFR gene has recently been associated with migraine with aura in a Japanese cohort (Kowa et al., 2000). The present study was designed to determine the prevalence of the MTHFR C677T mutation in Australian patients with migraine and to determine whether this mutation is associated with the disease in Caucasians. A large case-control study, consisting of 270 patients with migraine (167 with aura and 103 without aura), and 270 normal matched controls was investigated. Genotypic results indicated that the prevalence of the homozygous (T/T) genotype in migraine sufferers (15%) was higher than that of controls (9%) (P = 0.084). Furthermore, the frequency of the mutant (T/T) genotype in individuals with MA (19%) was significantly higher than in controls (9%) (P = 0.006). Interestingly, the risk of MA was ~2.5-fold higher in suffers possessing the homozygous variant (OR = 2.52, CI: 1.42 - 4.47, P = 0.0012). To confirm the MTHFR allelic association with MA, family-based tests were performed in an independent pedigrees group, where only those with MA were considered affected. Results from both the Pedigree Disequilibrium Test (PDT) and Family-Based Association Test (FBAT) analysis revealed slight, although not significant (PDT test, P = 132; and FBAT test, P = 0.390), over-transmission of the mutant allele (T) from parents to affected offspring. However, despite the MTHFR variant having a high heterozygosity (0.48), there were a limited number of informative transmissions for the MTHFR variant in the pedigree group resulting in reduced power for these tests. In conclusion, our results support the trends reported in the Japanese migraine study and suggest that the homozygous 677T gene variant causing mild hyperhomocysteinaemia, is a genetic risk factor for migraine, and indicate that further studies investigating the role of this gene are warranted. Mutations in various ion channel genes are responsible for neurovascular and other neurological disorders. Inherited ion channel mutations or "channelopathies" are increasingly found to be the cause of various neurological disorders in humans. Wittekindt and colleagues (1998) reported that the calcium-activated potassium channel (hKCa3) gene is a good candidate for schizophrenia and bipolar disorder (BD), as well as for other neurological disorders such as migraine. The hKCa3 gene is a neuronal small conductance calcium-activated potassium channel, which contains a polyglutamine tract, encoded by a polymorphic CAG repeat in the gene. The hKCa3 gene encodes a protein of 731 amino acids containing two adjacent polyglutamine sequences in its N-terminal domain separated by 25 amino acids. The C-terminal polyglutamine sequence is highly polymorphic in length (Austin et al., 1999). hKCa3 plays a critical role in determining the firing pattern of neurons via the generation of slow after-polarization pulses and the regulation of intracellular calcium channels (Kohler et al., 1996). Three distinct mutations in the a1 calcium channel gene have been shown to cause SCA-6, episodic ataxia-2 and familial hemiplegic migraine (FHM) (Ophoff et al., 1996). The hKCa3 gene contains a highly polymorphic CAG repeat that was initially mapped (Chandy et al., 1997) to a schizophrenia locus on chromosome 22 (Pulver et al., 1994). Recently Austin et al (1999) re-mapped hKCa3 and found it to reside on chromosome 1q21, a region that has been linked to FHM (Austin et al., 1999), a rare subtype of MA (Ducros et al., 1997; Gardner et al., 1998), and a region recently showing genetic linkage to typical migraine (Lea et al., 2002). The hKCa3 polymorphism results in small variations in polyglutamine number, similar to those that occur in the calcium channel a1a subunit gene (CACNA1A), which is encoded by CAG expansions and thought to cause Spinocerebellar Ataxia Type 6 via loss of channel function (Austin et al., 1999). Given the recent linkage of FHM to the region of chromosome 1q21, to which hKCa3 resides, and also linkage of typical migraine to this region, a large case-control study investigating this hKCa3 CAG marker and consisting of 270 migraine and 270 stringently matched healthy controls was undertaken. Our results indicated that there was no statistically significant difference in allele distributions for this marker between migraine and non-migraine patients (P >0.05). No significant difference in the allelic distribution was observed in the MA or MO groups when compared to controls (P >0.05) and there was no significant difference in CAG repeat length distribution between the migraine group and controls (P = 0.92), or between the MA and MO groups (P = 0.72) collectively. Hence, the CAG repeat in this gene does not show expansion in migraine. Overall, our results provide no genetic evidence to suggest that the hKCa3 CAG repeat polymorphism is involved in migraine aetiology in Australian Caucasians. Thus the involvement of the hKCa3 gene in migraine is not likely, although the hKCa3 gene remains an important candidate for other neurological disorders that may be linked to the 1q21.3 chromosomal region.
Style APA, Harvard, Vancouver, ISO itp.
5

Sundholm, James. "Analysis of Specific Migraine Candidate Genes Mapping to Human Chromosome 1". Thesis, Griffith University, 2003. http://hdl.handle.net/10072/367192.

Pełny tekst źródła
Streszczenie:
Migraine, comprised of migraine with aura (MA) and migraine without aura (MO), is a painful neurovascular disease, affecting approximately 16% of the general population. It is characterised by a wide variety of symptoms including headache, nausea and vomiting, and photo- and phonophobia. The disorder is complex involving not only multiple genes, but also specific environmental factors, which can induce attacks in genetically predisposed individuals. Hyperhomocysteinaemia is a known risk factor for cerebrovascular, peripheral vascular and coronary heart disease. The Methylenetetrahydrofolate Reductase (MTHFR) enzyme is involved in homocysteine metabolism. Furthermore, it has been reported that a homozygous mutation (677C to T; Ala to Val) in the 5,10-MTHFR gene is associated with an elevation in plasma homocysteine levels (Frosst et al., 1995). This common mutation in the MTHFR gene has recently been associated with migraine with aura in a Japanese cohort (Kowa et al., 2000). The present study was designed to determine the prevalence of the MTHFR C677T mutation in Australian patients with migraine and to determine whether this mutation is associated with the disease in Caucasians. A large case-control study, consisting of 270 patients with migraine (167 with aura and 103 without aura), and 270 normal matched controls was investigated. Genotypic results indicated that the prevalence of the homozygous (T/T) genotype in migraine sufferers (15%) was higher than that of controls (9%) (P = 0.084). Furthermore, the frequency of the mutant (T/T) genotype in individuals with MA (19%) was significantly higher than in controls (9%) (P = 0.006). Interestingly, the risk of MA was ~2.5-fold higher in suffers possessing the homozygous variant (OR = 2.52, CI: 1.42 - 4.47, P = 0.0012). To confirm the MTHFR allelic association with MA, family-based tests were performed in an independent pedigrees group, where only those with MA were considered affected. Results from both the Pedigree Disequilibrium Test (PDT) and Family-Based Association Test (FBAT) analysis revealed slight, although not significant (PDT test, P = 132; and FBAT test, P = 0.390), over-transmission of the mutant allele (T) from parents to affected offspring. However, despite the MTHFR variant having a high heterozygosity (0.48), there were a limited number of informative transmissions for the MTHFR variant in the pedigree group resulting in reduced power for these tests. In conclusion, our results support the trends reported in the Japanese migraine study and suggest that the homozygous 677T gene variant causing mild hyperhomocysteinaemia, is a genetic risk factor for migraine, and indicate that further studies investigating the role of this gene are warranted. Mutations in various ion channel genes are responsible for neurovascular and other neurological disorders. Inherited ion channel mutations or "channelopathies" are increasingly found to be the cause of various neurological disorders in humans. Wittekindt and colleagues (1998) reported that the calcium-activated potassium channel (hKCa3) gene is a good candidate for schizophrenia and bipolar disorder (BD), as well as for other neurological disorders such as migraine. The hKCa3 gene is a neuronal small conductance calcium-activated potassium channel, which contains a polyglutamine tract, encoded by a polymorphic CAG repeat in the gene. The hKCa3 gene encodes a protein of 731 amino acids containing two adjacent polyglutamine sequences in its N-terminal domain separated by 25 amino acids. The C-terminal polyglutamine sequence is highly polymorphic in length (Austin et al., 1999). hKCa3 plays a critical role in determining the firing pattern of neurons via the generation of slow after-polarization pulses and the regulation of intracellular calcium channels (Kohler et al., 1996). Three distinct mutations in the a1 calcium channel gene have been shown to cause SCA-6, episodic ataxia-2 and familial hemiplegic migraine (FHM) (Ophoff et al., 1996). The hKCa3 gene contains a highly polymorphic CAG repeat that was initially mapped (Chandy et al., 1997) to a schizophrenia locus on chromosome 22 (Pulver et al., 1994). Recently Austin et al (1999) re-mapped hKCa3 and found it to reside on chromosome 1q21, a region that has been linked to FHM (Austin et al., 1999), a rare subtype of MA (Ducros et al., 1997; Gardner et al., 1998), and a region recently showing genetic linkage to typical migraine (Lea et al., 2002). The hKCa3 polymorphism results in small variations in polyglutamine number, similar to those that occur in the calcium channel a1a subunit gene (CACNA1A), which is encoded by CAG expansions and thought to cause Spinocerebellar Ataxia Type 6 via loss of channel function (Austin et al., 1999). Given the recent linkage of FHM to the region of chromosome 1q21, to which hKCa3 resides, and also linkage of typical migraine to this region, a large case-control study investigating this hKCa3 CAG marker and consisting of 270 migraine and 270 stringently matched healthy controls was undertaken. Our results indicated that there was no statistically significant difference in allele distributions for this marker between migraine and non-migraine patients (P >0.05). No significant difference in the allelic distribution was observed in the MA or MO groups when compared to controls (P >0.05) and there was no significant difference in CAG repeat length distribution between the migraine group and controls (P = 0.92), or between the MA and MO groups (P = 0.72) collectively. Hence, the CAG repeat in this gene does not show expansion in migraine. Overall, our results provide no genetic evidence to suggest that the hKCa3 CAG repeat polymorphism is involved in migraine aetiology in Australian Caucasians. Thus the involvement of the hKCa3 gene in migraine is not likely, although the hKCa3 gene remains an important candidate for other neurological disorders that may be linked to the 1q21.3 chromosomal region.
Thesis (Masters)
Master of Philosophy (MPhil)
School of Health Sciences
Full Text
Style APA, Harvard, Vancouver, ISO itp.
6

Le, Houëdec Anne Bobin-Dubigeon Christine. "Les migraines à l'officine". [S.l.] : [s.n.], 2006. http://theses.univ-nantes.fr/thesemed/PHlehouedec.pdf.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Arend, Nicole Elizabeth. "Enhancing migraine diagnosis and treatment to improve quality of life in women with migraines". Honors in the Major Thesis, University of Central Florida, 2010. http://digital.library.ucf.edu/cdm/ref/collection/ETH/id/1349.

Pełny tekst źródła
Streszczenie:
This item is only available in print in the UCF Libraries. If this is your Honors Thesis, you can help us make it available online for use by researchers around the world by following the instructions on the distribution consent form at http://library.ucf.edu/Systems/DigitalInitiatives/DigitalCollections/InternetDistributionConsentAgreementForm.pdf You may also contact the project coordinator, Kerri Bottorff, at kerri.bottorff@ucf.edu for more information.
Bachelors
Nursing
Nursing
Style APA, Harvard, Vancouver, ISO itp.
8

Pinkerman, Brenda F. "Menstrually Related and Nonmenstrual Migraines in a Frequent Migraine Population: Features, Correlates, and Acute Treatment Differences". Ohio University / OhioLINK, 2006. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1141789064.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Pinkerman, Brenda F. "Menstrually related and nonmenstrual migraines in a frequent migraine population features, correlates, and acute traetment differences /". Ohio : Ohio University, 2006. http://www.ohiolink.edu/etd/view.cgi?ohiou1141789064.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

McPhee, Douglas P. "Chronic Migraines and Couples: A Grounded Theory of Adaptation to Chronic Migraines for Patients and their Partners". DigitalCommons@USU, 2018. https://digitalcommons.usu.edu/etd/7275.

Pełny tekst źródła
Streszczenie:
This study was completed to better understand and treat couples wherein one partner suffers from chronic migraines. I interviewed eight couples about their experiences in dealing with migraines as a patient, as a partner, and together. The interviews were transcribed and analyzed by a team of seven researchers. We developed a theory that can be used to understand how patients and their partners adapt to chronic migraines. The theory was grounded in the experiences of the patients and partners who were interviewed. We found that patients and partners alike dealt with burdens and costs associated with chronic migraines. Coping, healthcare, couple experience, and identity were found to be the means through which patients and partners adapted to their burdens. These concepts are broken down and discussed in greater detail. A model is provided that can be used to create a visual representation of how well a couple deals with migraines. Suggestions for couples who are dealing with chronic migraines, and for medical providers and therapists who work with couples affected by chronic migraines, are provided.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Migraines"

1

Brown, Anne K. Migraines. Detroit: Lucent Books, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

E, Williams Mary. Migraines. Detroit: Greenhaven Press, 2011.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Brown, Anne K. Migraines. Detroit: Lucent Books, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Presidential migraines. [Minn.?]: First Edition, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Anne, MacGregor. Comprendre les migraines. Montréal: Modus Vivendi, 2006.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Migraines and headaches. New York: Rosen Pub., 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Stafford, Diane. Migraines for dummies. New York, NY: Wiley Pub., 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Dyson, Sue. Migraines: A natural approach. Berkeley, CA: Ulysses Press, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Blau, J. N. Understanding headcahes and migraines. London: Published by Consumers' Association for Hodder & Stoughton, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Overcoming headaches and migraines. Eugene, Or: Harvest House Publishers, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Migraines"

1

Marcus, Dawn A., i Duren Michael Ready. "Accepting Migraines". W Discussing Migraine With Your Patients, 49–59. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6484-0_5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Engel, Joyce. "Migraines/Chronic Headaches". W Behavioral Approaches to Chronic Disease in Adolescence, 155–61. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-87687-0_13.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Russo, Antonio, Alessandro Tessitore i Gioacchino Tedeschi. "Neuroimaging in Migraines". W Neuroimaging of Pain, 267–95. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48046-6_10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Wright, Eric J., i William G. Austen. "Surgical Management of Migraines". W Diagnosis and Management of Head and Face Pain, 261–70. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-90999-8_21.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Johnson, Veronica A. "Migraines and Atmospheric Conditions". W Disability and Disaster, 91–94. London: Palgrave Macmillan UK, 2015. http://dx.doi.org/10.1057/9781137486004_11.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Dahlem, Markus A. "Migraines and Cortical Spreading Depression". W Encyclopedia of Computational Neuroscience, 1712–20. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-6675-8_507.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Leighton, Russell R., i Alexis P. Wieland. "The Aspirin/Migraines Software Package". W The Kluwer International Series in Engineering and Computer Science, 209–27. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2736-7_11.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Dahlem, Markus. "Migraines and Cortical Spreading Depression". W Encyclopedia of Computational Neuroscience, 1–10. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7320-6_507-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Dahlem, Markus A. "Migraines and Cortical Spreading Depression". W Encyclopedia of Computational Neuroscience, 1–9. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-7320-6_507-6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Dahlem, Markus A. "Migraines and Cortical Spreading Depression". W Encyclopedia of Computational Neuroscience, 1–9. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4614-7320-6_507-7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Migraines"

1

Ceddaha Zibi, A. "Migraine faciale à expression dentaire, à propos de trois cas". W 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603016.

Pełny tekst źródła
Streszczenie:
Migraine faciale à expression dentaire, à propos de trois cas. Anael CEDDAHA ZIBI1, Vanina LUCIANI2, Diane NGUYEN3, Audrey CHANLON3, Nathan MOREAU4,5 1 - Interne en chirurgie orale 2 - Etudiante en 6ème année de chirurgie dentaire, Faculté de Chirurgie dentaire, Université Paris Descartes 3 - Praticien attaché, consultation de diagnostic et traitement des douleurs chroniques oro-faciales, service de médecine bucco-dentaire, Hôpital Bretonneau, AP-HP, Paris 4 - Responsable de la consultation de diagnostic et traitement des douleurs chroniques oro-faciales, service de médecine bucco-dentaire, Hôpital Bretonneau, AP-HP, Paris 5 - MCU-PH en médecine et chirurgie orale, Faculté de Chirurgie Dentaire, Université Paris Descartes & Service de Médecine buccodentaire, Hôpital Bretonneau, AP-HP, Paris & Laboratoire de Neurobiologie Oro-Faciale, Université Paris Diderot La migraine est une affection neurovasculaire qui peut être invalidante, sa pathogénie n’est pas encore parfaitement élucidée aujourd’hui. Le plus souvent à type de céphalée, elle représente la céphalée primaire la plus fréquente. Si son diagnostic est aisé lorsqu’elle se présente sous forme de céphalée, il devient plus délicat devant des manifestations faciales de migraines moins typiques. Les migraines avec une atteinte oro-faciale stricte sont peu décrites dans la littérature. Notre étude portera sur trois cas de patients recrutés et suivis à la consultation douleur de l’hôpital Bretonneau ayant souffert de douleurs oro- faciales, étiquetées comme migraines. Ce diagnostic ayant été confirmé par la suite lors de leurs prise en charge en neurologie. Dans le cas des migraines à expression dentaire, la maladie si elle est méconnue risque d’entraîner des traitements dentaires abusifs et inadaptés, comme cela a été le cas pour ces trois patientes. L’errance diagnostique et la chronicité des douleurs engendrent une dégradation de la qualité de vie des malades, et impacte souvent leur relation affective et professionnelle. L’aspect économique des traitements dentaires à répétition chez ces patients n’est pas à négliger. Si la migraine est une maladie bénigne elle peut devenir invalidante. La forte prévalence des migraines dans la population générale et dans la population active en fait une des priorités de santé publique du fait de son retentissement économique. Les objectifs de la prise en charge thérapeutique prennent en compte l’éradication des facteurs déclenchant des crises, le traitement de la crise migraineuse, et un traitement de fond prophylactique lorsque la fréquence des crises est importante. La migraine demeure une maladie sous-diagnostiquée dans toutes ses formes d’expression. Un diagnostic précoce demeure pourtant indispensable pour une prise en charge optimale en particulier en cas de manifestations oro-faciales pures.
Style APA, Harvard, Vancouver, ISO itp.
2

Lines, Larry, Andrew Burton i Han‐xing Lu. "Migration without migraines". W SEG Technical Program Expanded Abstracts 1994. Society of Exploration Geophysicists, 1994. http://dx.doi.org/10.1190/1.1822747.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Muniz, Camila Osterne, Bruna Araújo Fernandes, Beatriz Murta Melo Oliveira, Raquel Rebouças Paiva, Daniele Santos Fonseca, Marina Behne Mucci, Maria Grasiele dos Anjos Gois i in. "Rates of hospitalizations for migraines and other cephalic algias syndromes is children between 2014 and 2020". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.700.

Pełny tekst źródła
Streszczenie:
Introduction: Migraine is the most common chronic headache in childhood, however, it is still little diagnosed in the pediatric group. Early crises can be very early, at 6 months of age. It may present in different ways according to the age group of the child and may or may not resemble the clinical picture of the associated manifestations that may aid in diagnosis. Methods and Objectives: The study used data available on the DataSus, in the category of hospitalization by the CID-10, in the group of less than 1 year, between 1 and 4 years, 5 and 9 years and 10 and 14 years, in the period from 2014 to 2020, to discuss the diagnosis of migraines and compare the prevalence of hospitalizations among children . Results: Between 2014 and 2020, the age group with the highest rate of hospitalization for migraine and other cephalic pain syndromes was 10-14 years, with an average of 57,13%, followed by 5-9 years (32,75%), 1-4 years (8,95%) and below 1 year (1,57%). Conclusion: Migraine has a semiological aspect that makes it difficult to identify in the pediatric group: symptoms. How diagnosis depends on a subjective report, children, especially the younger ones, become underdiagnosed. This can justify the higher incidence of hospitalizations among older children, with greater communication skills and a better description. Another factor is the absence of skilled professionals. Adaptation is necessary to assist in diagnosis, such as: associated clinical manifestations; Note; use of semi-structured interrogation and playful scales to spread the pain.
Style APA, Harvard, Vancouver, ISO itp.
4

Pereira, Camila Nakamura Perissê, Lamys Fernandes Kozak, Victor Fernandes Feitosa Braga, Pedro Henrique Bersan de Menezes i Alexandre Sampaio Rodrigues Pereira. "The use of erenumab for preventing migraine". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.191.

Pełny tekst źródła
Streszczenie:
Background: In 2018, calcitonin gene-related peptides (CGRP) were approved in the United States as the first class of specific migraine prevention drugs. Objectives: To analyze the efficacy and therapeutic safety of erenumab for preventing migraine. Methods: A narrative literature review was carried out by researching in the PubMed/MEDLINE and SciELO databases, using the descriptor “migraine disorders” and the keyword “erenumab” combined by the Boolean operator AND. Eight articles were selected, between 2017 and 2020. Results: The pathophysiology of migraine is related to CGRP through nociceptive modulation in the trigeminovascular system. Therefore, erenumab was developed, which is a human monoclonal antibody that binds selectively and potently to the canonical receptor of CGRP and acts as an antagonist of CGRP. Evidence indicates that the monthly dose of 70mg or 140mg reduces the frequency, quality and intensity of acute and chronic migraines. Studies report a decrease of two to six days of migraine using erenumab. The same adverse reactions occurred in both placebo and experimental groups, including upper respiratory tract viral infection, pain at the injection site and nausea. Conclusions: Erenumab is a promising drug, because it showed efficacy in the first days of treatment, absence of significant side effects and low rate of discontinuation. Aspects such as safety, effect durability, impact on quality of life and cost require further research.
Style APA, Harvard, Vancouver, ISO itp.
5

Soares, Samantha Lia Ziotti Bohn Gonçalves, Letícia Santana Ferreira Gonçalves, Emily Thauara de Souza, Pollyana Yuri Salles Suguinoshita, Luana Isla Rocha Alves, Anna Mariah R. ibeiro Oliveira, Thalia Castro Souza i Bárbara Machado Garcia. "Clinical correlation between Migraine and Generalized Anxiety Disorders: a literature review". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.154.

Pełny tekst źródła
Streszczenie:
Background: Migraine and anxiety are common neuro-psychiatric disorders in clinical practice, sharing symptoms and epidemiological factors among themselves. The presence of both pathologies in the same individual is frequently reported in the literature. Objectives: To report the clinical and epidemiological correlations established between generalized anxiety disorder and migraine. Methodology: Systematic review of studies published between 2016 and 2021, exploring the association between generalized anxiety disorders and Migraine. The descriptors “association”, “Migraines” and “Generalized Anxiety Disorder” were used in the LILACS, SCIELO and PUBMED databases. Fourteen articles were selected, mostly dealing with epidemiological studies. Results: Evidence suggests that these pathologies are associated and share common symptoms, pathophysiology and epidemiological factors. Studies corroborate that anxiety and painful sensation are more strongly associated with migraine than with other psychiatric illnesses. It has also demonstrated some characteristics of patients who are predisposed to develop both comorbidities such as smoke, low income and a history of other previous diseases. Common triggering factors such as pain, sleep disorders and stress can also contribute to the association between pathologies. Conclusions: Based on the studies analyzed in full, the high prevalence of both diseases in the same individual highlights the importance of research on the cause and consequence relationship between Anxiety and Migraine, since this is not yet clarified in the medical literature. In addition, paying attention to migraine correlation to generalized anxiety disorder increases the quality of life of the patient in the short and long term, as well as help in the choice of better treatments.
Style APA, Harvard, Vancouver, ISO itp.
6

Dannenberg, F., P. Bittigau, C. Prager, D. Atalay i A. M. Kaindl. "Don’t Miss Migraines in Patients with Drug-Resistant Epilepsy". W Abstracts of the 46th Annual Meeting of the Society for Neuropediatrics. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1739620.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Hassan, Refaat, Viral Gudiwala, Louise Jeynes i Arun Saraswatula. "365 Greater occipital nerve block as a treatment for paediatric migraines". W Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2022. http://dx.doi.org/10.1136/archdischild-2022-rcpch.354.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Tighe, Hannah, Heidi Wolfenden, James Springett, Lydia Babawale, Joseph Perks, Trishan Patel i Claire Shovlin. "Forced expiratory manoeuvres provoke nosebleeds and migraines in patients with hereditary haemorrhagic telangiectasia". W ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1326.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

John, Annie, i Wasiullah Shinwari. "88 Vitamin B2 (Riboflavin) as prophylaxis for migraines in children: a retrospective review". W RCPCH Conference Singapore. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjpo-2021-rcpch.51.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Tent, Michiel. "Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population". W European Headache Congress, redaktor Rachel Giles. Baarn, the Netherlands: Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/1377cf32.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Migraines"

1

Li, Xiao, GX Xu, FY Ling, ZH Yin, Y. Wei,, Y. Zhao, Xn Li, WC Qi, L. Zhao i FR Liang. The dose-effect association between electroacupuncture sessions and its effect on chronic migraine: a protocol of a meta-regression of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, grudzień 2022. http://dx.doi.org/10.37766/inplasy2022.12.0085.

Pełny tekst źródła
Streszczenie:
Review question / Objective: We will use a meta-regression approach to verify the dose-effect relationship between the number of electroacupuncture sessions and its effects on migraine. Condition being studied: Migraine is recurrent and chronic, requiring long-term control, but the side effects caused by long-term use limit the use of pharmacotherapy, like non-steroidal anti-inflammatory drugs (NSAIDS), ergoamines and opioids. With fewer side effects and lower cost, acupuncture is becoming a more attractive option for migraine. Relevant studies have confirmed the clinical effects of electroacupuncture on migraine and its effects on intracranial blood flow velocity, functional brain imaging and neuroinflammation. However, uncertainty exists regarding the dose-effect between electroacupuncture and migraine. In recent years, inspired by the dose-effect researches in pharmacology and epidemiology, researches focusing on the dose-effect association between acupuncture and diseases has also begun to emerge. So in this protocol, we designed to use a meta-regression approach to explore the optimal electroacupuncture dose for migraine.
Style APA, Harvard, Vancouver, ISO itp.
2

Halker Singh, Rashmi B., Juliana H. VanderPluym, Allison S. Morrow, Meritxell Urtecho, Tarek Nayfeh, Victor D. Torres Roldan, Magdoleen H. Farah i in. Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (AHRQ), grudzień 2020. http://dx.doi.org/10.23970/ahrqepccer239.

Pełny tekst źródła
Streszczenie:
Objectives. To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO®, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews. Review methods. We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients).Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials. Conclusions. A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
Style APA, Harvard, Vancouver, ISO itp.
3

Lee, Hee Jin, Min Cheol Chang, Yoo Jin Choo i Sae Yoon Kim. The Associations between Headache (Migraine and Tension-type Headache) and Psychotic Symptoms (Depression and Anxiety) in Pediatrics: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, październik 2022. http://dx.doi.org/10.37766/inplasy2022.10.0078.

Pełny tekst źródła
Streszczenie:
Review question / Objective: The purpose of this study was to investigate the association with specific psychiatric symptoms such as depression and anxiety in pediatric patients suffering from migraine and TTH. In our meta-analysis for a detailed evaluation of depression and anxiety, we attempted to review the research using various psychodiagnostic tools. Eligibility criteria: The detailed inclusion criteria for the network meta-analysis were studies with (1) inclusion of pediatric patients; (2) patients with migraine and TTH; (3) evaluation of association between headache (migraine or TTH) and psychotic symptoms (depression and anxiety); (4) comparison between group with headache (migraine or TTH) and control group; (5) using tools for evaluating degree of depression or anxiety; and (6) written in English. Review articles, case reports, letters, and studies with insufficient data or results were excluded.
Style APA, Harvard, Vancouver, ISO itp.
4

Charles, Andrew. Novel Therapeutic Targets for Chronic Migraine. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2013. http://dx.doi.org/10.21236/ada612867.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Charles, Andrew, i Peter Goadsby. Novel Therapeutic Targets for Chronic Migraine. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2012. http://dx.doi.org/10.21236/ada566633.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Charles, Andrew, i Peter Goadsby. Novel Therapeutic Targets for Chronic Migraine. Fort Belvoir, VA: Defense Technical Information Center, listopad 2014. http://dx.doi.org/10.21236/ada623382.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Research, Gratis. Green Light: A New Preventive Therapy for Migraine. Gratis Research, listopad 2020. http://dx.doi.org/10.47496/gr.blog.03.

Pełny tekst źródła
Streszczenie:
Manipulating the ability of green light to create the least amount of electrical signals in retina and brain cortex, green light therapy offers an excellent therapeutic role in reducing migraine pain and improves the quality of life
Style APA, Harvard, Vancouver, ISO itp.
8

VanderPluym, Juliana H., Rashmi B. Halker Singh, Magdoleen H. Farah, Kelly E. Viola, Bashar Hasan, Samer Saadi, Sahrish Shah i in. Acute Treatments for Episodic Migraine: Surveillance Report 3. Agency for Healthcare Research and Quality (AHRQ), sierpień 2022. http://dx.doi.org/10.23970/ahrqepcmigrainesurveillance3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Pluym, Juliana H. Vande, Rashmi B. Halker Singh, Magdoleen H. Farah, Kelly E. Viola, Bashar Hasan, Samer Saadi, Sahrish Shah i in. Acute Treatments for Episodic Migraine: Surveillance Report 2. Agency for Healthcare Research and Quality (AHRQ), kwiecień 2022. http://dx.doi.org/10.23970/ahrqepcmigrainesurveillance2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Tsou, Amy, Benjamin Rouse, Aaron Bloschichak i Jonathan Treadwell. Drugs and Devices for Migraine Prevention: Interactive Evidence Maps. Patient-Centered Outcomes Research Institute (PCORI), luty 2021. http://dx.doi.org/10.25302/emv1.2021.2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Migraines” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii